Crossmark

Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma

Crossref DOI link: https://doi.org/10.1007/s12308-019-00344-0

Published Online: 2019-02-14

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Robetorye, Ryan S. http://orcid.org/0000-0002-9848-3295
Ramsower, Colleen A.

Rosenthal, Allison C.

Yip, Tameson K.

Wendel Spiczka, Amy J.

Glinsmann-Gibson, Betty J.

Rimsza, Lisa M.
Funding

Funding for this research was provided by:

Center for Individualized Medicine, Mayo Clinic (N/A)

Division of Cancer Epidemiology and Genetics, National Cancer Institute (U01CA57581)
License Information

Text and Data Mining valid from 2019-02-14

Version of Record valid from 2019-02-14
More Information

Article History

Received: 16 December 2018

Accepted: 31 January 2019

First Online: 14 February 2019

Compliance with ethical standards

: This study was performed with Mayo Clinic Arizona Institutional Review Board approval under protocol #17-006519.

: MDAZL: Center for Individualized Medicine, Mayo Clinic.L.M.R. is a co-inventor on a patent for the NanoString technology used in this manuscript but has received no licensing fees or royalty payments.Other authors declare that they have no conflict of interest.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below